Clinical trials: Predictive Biomarkers
Treatment Resistant Depression
Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms
This study will be an open-label 6-week (30 session) trial of active repetitive transcranial magnetic stimulation (rTMS) using a fixed frequency (10 Hz) but varying stimulation intensities using a 3+3 study design for safety and…
- Trial name
- NCT02611206
- Testing
- Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Threatened Preterm Labor
Maternal Serum Level of ACTH as a Predictive Marker of Preterm Labor in Patients With Threatened Preterm Labor
The aim of this study is use of ACTH as a predictive marker in patients of threatened preterm labor .
- Trial name
- PTL (NCT01773135)
- Testing
- collection of blood sample and tocolysis adminstration
- Where
- Egypt
- Volunteers
- 262 people
- Sponsor
- Ain Shams Maternity Hospital
Rheumatoid Arthritis
A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250)
This 14-week non-interventional study will observe patients with rheumatoid arthritis (RA) who are being treated with infliximab for the first time, in order to learn about their disease characteristics.
- Trial name
- REMARK (NCT00705289)
- Testing
- Infliximab
- Volunteers
- 728 people
- Sponsor
- Merck Sharp & Dohme LLC
Growth Hormone Deficiency
Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects…
- Trial name
- OraGrowtH210 (NCT04614337)
- Testing
- LUM-201, rhGH Norditropin® pen (34 µg/kg)
- Where
- 43 sites in United States, Australia and 4 more
- Volunteers
- 104 people
- Sponsor
- Lumos Pharma
Sepsis, Necrotising Enterocolitis Neonatal
Integrated Predictive Monitoring for Sepsis and Necrotizing Enterocolitis
Behind the scenes pilot trial in the computer lab involving chart review to use neonatal intensive care unit data to create computer models predicting sepsis and necrotizing enterocolitis in very small premature infants
- Trial name
- PREMO (K) (NCT07254559)
- Testing
- No Intervention: Observational Cohort
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Virginia